Atsena Therapeutics, Inc.

Atsena Therapeutics, based in Durham, North Carolina, develops innovative gene therapy solutions aimed at treating inherited retinal diseases and preventing blindness through advanced clinical trials. Founded in 2019 in Durham, North Carolina, Atsena Therapeutics specializes in gene therapy for retinal diseases. The company was established by Sanford Boye and Shannon Boye, with Patrick Ritschel serving as CEO. Atsena has successfully completed 4 deals, with its most recent funding round being a Series C in March 2025, raising USD 90.

000 mn led by Bain Capital Life Sciences, with participation from various other investors. The total amount raised by the company now stands at USD 90. 000 mn, with a current valuation of USD 295. 962 mn.

Atsena Therapeutics focuses on clinical-stage gene therapies that aim to address inherited retinal diseases, particularly those that can lead to blindness. Their primary therapies are currently in Phase I/II clinical trials, targeting conditions such as X-linked retinoschisis (XLRS) and GUCY2D-associated Leber congenital amaurosis (LCA1). Utilizing an adeno-associated virus (AAV) technology platform, these therapies deliver genetic material directly to retinal cells, striving to restore vision in affected patients. The company's pipeline also includes therapies for MYO7A-associated Usher syndrome (USH1B), indicating a thorough approach to various hereditary retinal conditions, primarily aimed at the pediatric population in North America and Europe.

Atsena Therapeutics generates revenue through clinical partnerships and collaborations that support its gene therapy initiatives. Revenue is anticipated from partnerships with research institutions and healthcare entities involved in clinical trials, as well as potential milestone payments linked to the advancement of their therapies. The company may also pursue collaborative agreements with pharmaceutical companies to commercialize its therapies following successful trials. Given its current product development stage, revenue streams are expected to primarily come from developmental collaborations rather than direct sales.

Atsena Therapeutics plans to utilize the USD 90. 000 mn raised in its Series C funding round to advance its lead program, ATSN-201. The company is focused on launching new gene therapies targeted at various inherited retinal diseases and expanding its market presence into North America and Europe by 2025. The recently raised funds will facilitate the ongoing clinical trials of its innovative therapies, with a strong emphasis on addressing the needs of patients suffering from genetic retinal disorders.